Clinical Trial Detail

NCT ID NCT02966587
Title Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Recruitment Withdrawn
Gender male
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

prostate cancer

Therapies

Durvalumab

Age Groups: adult senior

No variant requirements are available.